[go: up one dir, main page]

PL3688155T3 - Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar) - Google Patents

Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)

Info

Publication number
PL3688155T3
PL3688155T3 PL18803487.0T PL18803487T PL3688155T3 PL 3688155 T3 PL3688155 T3 PL 3688155T3 PL 18803487 T PL18803487 T PL 18803487T PL 3688155 T3 PL3688155 T3 PL 3688155T3
Authority
PL
Poland
Prior art keywords
icar
manufacturing
antigen receptor
chimeric antigen
universal platform
Prior art date
Application number
PL18803487.0T
Other languages
English (en)
Inventor
Gideon Gross
Will Gibson
Dvir Dahary
Merav Beiman
Original Assignee
Immpact-Bio Ltd.
Gavish-Galilee Bio Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immpact-Bio Ltd., Gavish-Galilee Bio Applications Ltd filed Critical Immpact-Bio Ltd.
Publication of PL3688155T3 publication Critical patent/PL3688155T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18803487.0T 2017-09-28 2018-09-28 Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar) PL3688155T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564454P 2017-09-28 2017-09-28
US201862649429P 2018-03-28 2018-03-28
PCT/US2018/053583 WO2019068007A1 (en) 2017-09-28 2018-09-28 UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)

Publications (1)

Publication Number Publication Date
PL3688155T3 true PL3688155T3 (pl) 2023-09-11

Family

ID=64308791

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18803487.0T PL3688155T3 (pl) 2017-09-28 2018-09-28 Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)

Country Status (17)

Country Link
US (3) US11660315B2 (pl)
EP (1) EP3688155B1 (pl)
JP (2) JP2020535814A (pl)
KR (1) KR20200071740A (pl)
CN (1) CN111465693A (pl)
AU (1) AU2018338975A1 (pl)
BR (1) BR112020006106A2 (pl)
CA (1) CA3077174A1 (pl)
DK (1) DK3688155T5 (pl)
ES (1) ES2941966T3 (pl)
FI (1) FI3688155T3 (pl)
HU (1) HUE061502T2 (pl)
IL (1) IL273598A (pl)
MX (1) MX2020003526A (pl)
PL (1) PL3688155T3 (pl)
PT (1) PT3688155T (pl)
WO (1) WO2019068007A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
EP3856236B1 (en) * 2018-09-28 2023-05-17 ImmPACT-Bio Ltd. Methods for identifying activating antigen receptor (acar)/inhibitory chimeric antigen receptor (icar) pairs for use in cancer therapies
GB201820157D0 (en) * 2018-12-11 2019-01-23 Imperial Innovations Ltd Method of treatment
SG11202111130SA (en) * 2019-04-30 2021-11-29 Senti Biosciences Inc Chimeric receptors and methods of use thereof
MX2022001711A (es) * 2019-08-09 2022-05-10 A2 Biotherapeutics Inc Receptores en la superficie celular que responden a la perdida de heterocigosidad.
EP4013494A1 (en) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
US20220389075A1 (en) 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
BR112022011399A2 (pt) 2019-12-11 2022-08-30 A2 Biotherapeutics Inc Receptor de antígeno quimérico baseado em lilrb1
EP4107175A4 (en) * 2020-02-20 2024-03-20 Senti Biosciences, Inc. ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
EP4107174A4 (en) * 2020-02-20 2024-10-30 Senti Biosciences, Inc. ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
WO2021173193A1 (en) * 2020-02-24 2021-09-02 The Regents Of The University Of California Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
WO2021252635A1 (en) * 2020-06-11 2021-12-16 A2 Biotherapeutics, Inc. Compositions and methods for treating cancers
CN114058589B (zh) * 2020-07-30 2023-05-12 华东师范大学 具有嵌合抗原受体修饰的免疫细胞、制备方法和药物
AU2021329375A1 (en) * 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
KR20250140123A (ko) 2020-08-20 2025-09-24 에이투 바이오쎄라퓨틱스, 인크. 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
MX2023002104A (es) * 2020-08-20 2023-07-10 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para egfr.
CN112194726B (zh) * 2020-09-02 2023-06-23 沣潮医药科技（上海）有限公司 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用
CA3194034A1 (en) * 2020-09-04 2022-03-10 ImmPACT Bio USA Inc. Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies
WO2022061272A1 (en) 2020-09-21 2022-03-24 A2 Biotherapeutics, Inc. Engineered immune cells
CN112194728B (zh) * 2020-09-22 2023-07-11 沣潮医药科技（上海）有限公司 用于内毒素清除的嵌合抗原受体及其应用
EP4240403A2 (en) * 2020-11-04 2023-09-13 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor comprising an antigen binding domain specific for msln having a specificity for tumor cells
US11572407B2 (en) 2020-11-18 2023-02-07 Pionyr Immunotherapeutics, Inc. Anti-MARCO antibodies and uses thereof
CN114832105B (zh) * 2021-02-01 2023-08-04 复旦大学附属中山医院 一种C7orf50基因或蛋白的抑制剂的用途
JP2024507129A (ja) 2021-02-16 2024-02-16 エー２ バイオセラピューティクス， インコーポレイテッド Ｈｅｒ２陽性がんを治療するための組成物及び方法
US20240226297A9 (en) * 2021-03-02 2024-07-11 The Trustees Of The University Of Pennsylvania Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes
CN113122543B (zh) * 2021-04-01 2024-05-17 厦门大学 唾液酸结合性免疫球蛋白样凝集素-15蛋白的核酸适配体及其应用
CN115702939A (zh) * 2021-08-05 2023-02-17 杭州星鳌生物科技有限公司 载物脂质体的多靶点复合体及含其的载药平台与应用
WO2023076912A2 (en) * 2021-10-26 2023-05-04 ImmPACT Bio USA Inc. Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies
CN114517185B (zh) * 2022-01-17 2023-04-28 华东师范大学 嵌合抗原受体nk细胞及其制备方法和应用
WO2023150768A2 (en) * 2022-02-07 2023-08-10 Oregon Health & Science University Biomarkers for acute myeloid leukemia and uses thereof
EP4490276A2 (en) * 2022-03-08 2025-01-15 A2 Biotherapeutics, Inc. Engineered receptors specific to hla-e and methods of use
CN116064771A (zh) * 2022-09-27 2023-05-05 中山大学 一种促进细胞铁死亡的基因的功能确定及应用
CN115807090B (zh) * 2022-11-17 2025-06-17 中国医学科学院肿瘤医院 Slamf9在肿瘤免疫治疗中的应用
US20240368273A1 (en) * 2023-05-03 2024-11-07 PELL Bio-Med Technology Co., Ltd. Murine anti-cd19 chimeric antigen receptor for treating cancer
WO2024232668A1 (ko) * 2023-05-09 2024-11-14 세종대학교산학협력단 항 ptgfrn 단일클론항체 및 그 용도
CN116773790B (zh) * 2023-08-18 2023-11-28 南京普恩瑞生物科技有限公司 一种肿瘤组织her2梯度检测产品的制备方法和应用
CN117567651B (zh) * 2024-01-15 2024-03-26 中国人民解放军东部战区总医院 协同表达血管内皮黏附分子vcam1的嵌合抗原受体及其应用
CN119015428B (zh) * 2024-10-29 2024-12-20 中国人民解放军总医院第三医学中心 一种敲低tmem91诱导肾癌细胞死亡和肿瘤免疫治疗肾癌的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2607498B1 (en) 2008-09-03 2017-05-03 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN105246504A (zh) 2013-03-15 2016-01-13 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2015075468A1 (en) 2013-11-21 2015-05-28 Ucl Business Plc Cell
CN105917007A (zh) 2014-01-16 2016-08-31 克洛维斯肿瘤有限公司 Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
WO2016075612A1 (en) 2014-11-12 2016-05-19 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
KR102624023B1 (ko) 2015-02-24 2024-01-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 결합-촉발된 전사 스위치 및 이들의 이용 방법
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
KR20190052697A (ko) * 2016-09-28 2019-05-16 가비쉬-가릴리 바이오 어플리케이션스 리미티드. 암의 신규한 항원 지표를 표적화하는 ｃａｒ 요법을 위한 보편적 플랫폼
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
EP3856236B1 (en) 2018-09-28 2023-05-17 ImmPACT-Bio Ltd. Methods for identifying activating antigen receptor (acar)/inhibitory chimeric antigen receptor (icar) pairs for use in cancer therapies
CN113286814A (zh) 2018-10-31 2021-08-20 德里尼亚公司 多价调节性t细胞调节子

Also Published As

Publication number Publication date
CA3077174A1 (en) 2019-04-04
US11660315B2 (en) 2023-05-30
DK3688155T5 (da) 2024-08-26
FI3688155T3 (fi) 2023-03-30
EP3688155A1 (en) 2020-08-05
KR20200071740A (ko) 2020-06-19
IL273598A (en) 2020-05-31
US20210244759A1 (en) 2021-08-12
US20240139238A1 (en) 2024-05-02
JP2023104959A (ja) 2023-07-28
BR112020006106A2 (pt) 2020-11-17
WO2019068007A1 (en) 2019-04-04
MX2020003526A (es) 2020-09-14
DK3688155T3 (da) 2023-04-03
HUE061502T2 (hu) 2023-07-28
JP2020535814A (ja) 2020-12-10
PT3688155T (pt) 2023-04-11
EP3688155B1 (en) 2023-01-04
US20200261499A1 (en) 2020-08-20
ES2941966T3 (es) 2023-05-29
AU2018338975A1 (en) 2020-04-16
CN111465693A (zh) 2020-07-28

Similar Documents

Publication Publication Date Title
PL3688155T3 (pl) Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
IL263220A (en) Cd33 specific chimeric antigen receptors
CL2018002711S1 (es) Automóvil
EP3680328A4 (en) TECHNIQUE FOR THE PREPARATION OF UNIVERSAL T-LYMPHOCYTES WITH CHEMICAL ANTIGENIC RECEPTOR
HUE047929T2 (hu) Kiméra antigén receptor
DK3126380T3 (da) Kimærisk antigen receptor-signalsystem (car)
CL2018002398S1 (es) Automóvil
HUE051700T2 (hu) Anti-PD-1 antitestek
DK3283110T3 (da) Antistoffer rettet mod interleukin-36-receptor (il-36r)
IL281428A (en) Chimeric antigen receptor
CL2018002666S1 (es) Automóvil
LT3183268T (lt) Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
EP3481690A4 (en) TEST PREDICTIONS FOR AUTONOMOUS VEHICLES
IL263764A (en) Anti-cd19 antibody formulations
IL268545B (en) Cleaning formulations
DK3698520T3 (da) System til kommunikationsrouting
IL280054A (en) Articulated robotic platform
ITUB20161088A1 (it) Dispositivo esoscheletrico per la mano
EP3604344A4 (en) CHEMICAL ANTIGENIC RECEPTOR
EP3440051A4 (en) AGROISTS OF NEUROPEPTIDE RECEPTOR (NPSR)
MA45458A (fr) Plate-forme de transport
DK3328886T3 (da) Tungkæde antistoffer over for ang-2
EP3959132C0 (en) OFF-CENTRE PARACHUTE FLIGHT INTERRUPTION SYSTEM
EP3898123C0 (en) ROBOTIC SYSTEM
DK3539639T3 (da) Afstøvningsindretning